First Manhattan CO Cti Biopharma Corp Transaction History

First Manhattan CO

  • $29.6 Billion
  • Q1 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022
SELL
$1.9 - $5.23 $62 - $172
-33 Closed
0 $0
Q4 2018

Jan 30, 2019
SELL
$0.73 - $2.19 $2 - $6
-3 Reduced 8.33%
33 $0
Q3 2017

Oct 25, 2017
BUY
$3.12 - $3.65 $112 - $131
36
36 $0

About CTI BIOPHARMA CORP

CTIC Quotes by TradingView
  • Ticker CTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,385,000
  • Market Cap $1.04B
  • Description
  • CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...
More about CTIC
Track This Portfolio

Track First Manhattan CO Portfolio

Follow First Manhattan CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

News

Stay updated on First Manhattan CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email